Android app on Google Play

Stifel Nicolaus Initiates/Restarts BIIB, AFFY, CELG, GILD, ACOR, ARQL, ARIA, EXEL, BSTC at Buy, AMGN, DNDN at Hold

March 15, 2012 7:48 AM EDT Send to a Friend
Get Alerts BIIB Hot Sheet
Price: $339.97 +0.39%

Rating Summary:
    21 Buy, 7 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 13 | New: 4
Trade BIIB Now!
Join SI Premium – FREE
Stifel Nicolaus' Joel Sendek initiated and resumed coverage on the following Biotech and Drug stocks Thursday morning:
  • Biogen (Nasdaq: BIIB) with a Buy rating and a $144 price target
  • Affymax (Nasdaq: AFFY) with a Buy rating and a $19 price target
  • Celgene (Nasdaq: CELG) with a Buy rating and a $87 price target
  • Gilead (Nasdaq: GILD) with a Buy rating and a $57 price target
  • Acorda Therapeutics (Nasdaq: ACOR) with a Buy rating and a $34 price target
  • ArQule (Nasdaq: ARQL) with a Buy rating and a $13 price target
  • Ariad Pharma (Nasdaq: ARIA) with a Buy rating and a $19 price target
  • Exelixis (Nasdaq: EXEL) with a Buy rating and a $8 price target
  • BioSpecifics Technologies (Nasdaq: BSTC) with a Buy rating and a $ price target
  • Amgen (Nasdaq: AMGN) with a Hold rating
  • Dendreon (Nasdaq: DNDN) with a Hold rating
Check out our Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.




You May Also Be Interested In


Related Categories

New Coverage

Related Entities

Stifel Nicolaus

Add Your Comment